Skip to main content
. 2022 Dec 2;11(12):2395. doi: 10.3390/antiox11122395

Figure 2.

Figure 2

Roles of the DEX microinjection to the paraventricular nucleus (PVN) on LPS-induced RSNA, MAP and HR changes. The PVN microinjection was carried out 24 h after the intraperitoneal injection of LPS. (A) Representative images showing the roles of DEX (0.4 nmol) on LPS-induced RSNA, MAP and HR changes; (B) dose-effects of DEX (0, 0.004, 0.04 and 0.4 nmol) (* p < 0.05 vs. 0 nmol); (C) time-effects of DEX († p < 0.05 vs. PBS); (D) effects of PVN microinjection of DEX (0.4 nmol) on LPS-induced RSNA, MAP and HR changes; (E) effects of DEX (0.4 nmol) on LPS-induced changes in norepinephrine level; (F) effects of DEX (0.4 nmol) on LPS-induced changes in plasma TNF-α and IL-1β levels (* p < 0.05. n = 6).